Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:30:225-253.
doi: 10.1007/978-3-031-21054-9_10.

Targeted Treatments for Fragile X Syndrome

Devon Johnson  1 , Courtney Clark  1 , Randi Hagerman  1   2
Affiliations

Targeted Treatments for Fragile X Syndrome

Devon Johnson et al. Adv Neurobiol. 2023.

Abstract

The histories of targeted treatment trials in fragile X syndrome (FXS) are reviewed in animal studies and human trials. Advances in understanding the neurobiology of FXS have identified a number of pathways that are dysregulated in the absence of FMRP and are therefore pathways that can be targeted with new medication. The utilization of quantitative outcome measures to assess efficacy in multiple studies has improved the quality of more recent trials. Current treatment trials including the use of cannabidiol (CBD) topically and metformin orally have positive preliminary data, and both of these medications are available clinically. The use of the phosphodiesterase inhibitor (PDE4D), BPN1440, which raised the level of cAMP that is low in FXS has very promising results for improving cognition in adult males who underwent a controlled trial. There are many more targeted treatments that will undergo trials in FXS, so the future looks bright for new treatments.

Keywords: AFQ056; Arbaclofen; FXTAS; Fragile X syndrome; Medications; Metformin; Minocycline; Premutation; Treatments.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004;10:31–41. - PubMed - DOI
    1. Thurman AJ, McDuffie A, Kover ST, Hagerman RJ, Abbeduto L. Autism symptomatology in boys with fragile X syndrome: a cross sectional developmental trajectories comparison with nonsyndromic autism spectrum disorder. J Autism Dev Disord. 2015;45:2816–32. - PubMed - PMC - DOI
    1. Cornish K, Steele A, Monteiro CRC, Karmiloff-Smith A, Scerif G. Attention deficits predict phenotypic outcomes in syndrome-specific and domain-specific ways. Front Psychol. 2012;3:227. - PubMed - PMC - DOI
    1. Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord. 2011;3:57–67. - PubMed - DOI
    1. Hess KL, Morrier MJ, Heflin LJ, Ivey ML. Autism treatment survey: services received by children with autism spectrum disorders in public school classrooms. J Autism Dev Disord. 2008;38:961–71. - PubMed - DOI

LinkOut - more resources